LIPID-LOWERING EFFECT OF TENOFOVIR IN PATIENTS WITH CHRONIC HEPATITIS B

Hospital Universitario Infanta Cristina, Pharmacy Department, Parla (Madrid), Spain.

Some studies have suggested a lipid-lowering effect of tenofovir (TDF) in HIV infected patients who take antiretroviral therapy.

PURPOSE
To assess lipid-lowering effect of TDF in patients with chronic hepatitis B (CHB)

MATERIALS AND METHODS

• Retrospective single-institution study.
• Inclusion criteria: adults with CHB, not HIV-coinfected, treated with tenofovir for at least one month.
• Demographic and treatment data (prior antiviral treatment, lipid-lowering therapy) were collected.
• Total cholesterol (TC) and triglycerides basal values were compared with those obtained 3-6 months after treatment onset.
• Mean values were compared using two-tailed Student´s test.

RESULTS

18 patients included. Ten patients (56%) were male. Mean (±SD) age was 47,7±10,8 years. None of the patients took lipid-lowering agents at baseline or during the study. Seven patients (38,9%) received other hepatitis B treatment before tenofovir.

<table>
<thead>
<tr>
<th>Basal</th>
<th>After tenofovir</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC</td>
<td>202,4±38,9</td>
<td>174,6±30,9</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>96,2±45,2</td>
<td>97,2±49,2</td>
</tr>
</tbody>
</table>

Sixteen patients (89%) improved TC levels.

CONCLUSIONS

➢ TC decreased significantly over the study period for most patients
➢ TDF did not seem to have a positive effect on triglycerides